Community Medical Services

What Community Medical Services does

Community Medical Services (CMS) is a privately held, multi-site opioid treatment program (OTP) founded in 1983 in Phoenix, Arizona. The company provides outpatient medication-assisted treatment (MAT) for individuals with opioid use disorder (OUD), delivering FDA-approved pharmacotherapies—including methadone, buprenorphine (Suboxone, Sublocade, Brixadi), and naltrexone (Vivitrol)—alongside individual and group counseling, certified peer support services, and specialized programs for pregnant women, justice-involved individuals, and emergency department referrals. CMS operates more than 70 clinic locations across 11 U.S. states (Alaska, Arizona, Colorado, Indiana, Michigan, Minnesota, Montana, North Dakota, Ohio, Oregon, Texas, and Wisconsin), including the nation's first 24-hour Opioid Treatment on Demand center in Phoenix, and it maintains a central laboratory in Scottsdale, Arizona that processes approximately 100,000 urine drug screens per quarter. Its proprietary digital tool, the Recovery Connect mobile app, is described as clinically proven to double patient odds of remaining in treatment when engaged in the first week.

CMS monetizes primarily through recurring Medicaid reimbursement across its operating states, supplemented by commercial insurance and federal block grant funding (e.g., the Substance Use Prevention, Treatment and Recovery Services Block Grant for qualifying Arizona residents). Pricing is structured around ongoing clinical services rather than per-episode transactions, and the company emphasizes low-barrier access: no waitlists, walk-in same-day treatment, transportation assistance, telehealth methadone initiation, and guest dosing for patients traveling across its network. Distribution combines direct-to-consumer intake (phone, walk-in, website) with a deep referral ecosystem spanning hospitals, EMS/first responders, correctional facilities, specialty courts, OBGYNs, primary care, homeless shelters, harm reduction coalitions, VA, and DCS. The company is CARF-accredited, AATOD-member, and Certified B Corporation (approximately March 2024).

Strategic posture is one of multi-state rollup: CMS has executed three disclosed acquisitions (Premier Care and Maintenance And Recovery Services in November 2018; Restorative Health and Recovery in May 2020) and continued organic clinic openings through 2024, particularly in Colorado and Ohio. Leadership was refreshed in 2023-2024 with the appointments of a Chief Science Officer, a COO, and a CFO with PE-backed healthcare finance experience, suggesting preparation for further scale or institutional capital activity. Ownership is private and management-led, with no disclosed parent, venture, or private equity sponsor at the date of input.

Name

Community Medical Services

Legal name

Community Medical Services

Website

https://communitymedicalservices.org

Company type

Private

Founded year

1983

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Community Medical Services is a privately held, multi-site opioid treatment program operating 70+ clinics across 11 U.S. states, providing FDA-approved medication-assisted treatment (methadone, buprenorphine, naltrexone) combined with counseling and peer support for individuals with opioid use disorder.

Ownership category

akta.pro rank

Product category

Opioid Use Disorder Treatment Services

NAICS

Outpatient Mental Health and Substance Abuse Centers (621420), Outpatient Mental Health and Substance Abuse Centers (62142)

SIC

Services-Specialty Outpatient Facilities, Nec (8093), Services-Health Services (8000)

akta.pro primary industry

Medication-Assisted Treatment (MAT) & Opioid Treatment Programs (OTPs) (HLAFACAG)

akta.pro secondary industries

Outpatient Substance Use Treatment Programs (IOP/PHP/OP) (HLAFACAF), Substance Use Recovery & Harm Reduction Support Services (BPAGAEAO)

Keywords

• Medication-assisted treatment
• Opioid treatment program
• Substance abuse counseling
• Outpatient addiction recovery
• Methadone buprenorphine treatment

Headquarters

HQ city

Phoenix

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales, Supply Chain

Revenue model

1. Medicaid Reimbursement: CMS accepts Medicaid and other insurance plans across operating states including Alaska, Arizona, Colorado, Indiana, Michigan, Minnesota, Montana, North Dakota, Ohio, Oregon, Texas, and Wisconsin. Medicaid is the primary reimbursement source for substance use disorder treatment services.
2. Grant Funding: Arizona residents may qualify for grant funding under the federal Substance Use Prevention, Treatment and Recovery Services Block Grant (SUBG). Grant funding may be available to those who qualify.

Pricing tiers

Go-to-market motion2 records

Distribution channels7 records

Marketing channels5 records

Core offering

Community Medical Services delivers outpatient medication-assisted treatment (MAT) for opioid use disorder through 70+ clinic locations across 11 U.S. states, prescribing FDA-approved medications (Methadone, Buprenorphine/Suboxone, Sublocade, Brixadi, and Naltrexone/Vivitrol) alongside evidence-based addiction counseling, certified peer support, pregnancy and women's health programs, guest dosing, telehealth initiation, and the Recovery Connect mobile app. The organization's defining feature is low-barrier, same-day, walk-in access — including the country's first 24-hour Opioid Treatment on Demand center in Phoenix — reimbursed primarily through Medicaid and commercial insurance.

Product overview

Community Medical Services operates a multi-site opioid treatment program (OTP) offering outpatient medication for opioid use disorder (MOUD). The core portfolio is anchored by six FDA-approved medication treatments — Methadone, Suboxone®, Buprenorphine, Naltrexone, Brixadi, and Sublocade® — which work through different pharmacological mechanisms (full agonist, partial agonist, and antagonist) to stabilize patients and reduce cravings. These medications are supported by behavioral health services including individual/group addiction counseling and peer support provided by Certified Peer Support Specialists. The company also offers the Recovery Connect mobile app as a complementary digital tool enabling 24/7 counselor communication and treatment tracking. Additional services include pregnancy and women's health programs, guest dosing for traveling patients, telehealth initiation, and urine drug screen testing. With 70+ clinic locations across multiple states including the nation's first 24-hour Opioid Treatment on Demand center in Phoenix, the company provides same-day treatment and walk-in services.

Differentiator

Problem solved

Functional benefit

Brands

• Recovery Connect: A groundbreaking mobile application that provides 24/7 access to recovery-focused interventions and virtual communication with counselors. Patients using the app in their first week double their odds of staying in treatment.

Products and services

• Methadone Treatment FDA-approved long-acting opioid agonist medication for opioid use disorder that stabilizes patients and prevents withdrawal symptoms, allowing patients to focus on recovery; administered under supervised dosing at CMS outpatient clinics.
• Suboxone® Treatment FDA-approved medication combining buprenorphine and naloxone to reduce cravings and withdrawal symptoms while preventing misuse, administered as a sublingual tablet or film as part of outpatient MAT.
• Buprenorphine Treatment Partial opioid agonist medication that binds to brain receptors to alleviate withdrawal symptoms and cravings without euphoric effects, available in multiple forms including sublingual and injectable options for moderate-to-severe opioid use disorder.
• Naltrexone (Vivitrol®) Treatment Potent opioid antagonist that blocks the effects of illicit opioids, available as a daily pill or monthly injectable (Vivitrol®), reducing cravings and supporting sustainable recovery for patients with opioid use disorder.
• Brixadi Treatment FDA-approved extended-release buprenorphine injection administered weekly or monthly, offering flexible dosing options for moderate to severe opioid use disorder and helping maintain treatment continuity.
• Sublocade® Treatment FDA-approved extended-release monthly buprenorphine injection that reduces cravings and withdrawal symptoms, available in 100mg and 300mg doses for sustained maintenance therapy.
• Pregnancy & Women's Health Program Specialized medication-assisted treatment services for pregnant and postpartum women with opioid use disorder, coordinating with OBGYN and other providers, including support for breastfeeding mothers on MAT, to protect both mother and baby.
• Addiction Counseling Programs Individual and group addiction counseling services using evidence-based practices that help clients develop healthy coping strategies and address the psychological aspects of substance use disorder alongside medication treatment.
• Peer Support Services Services provided by Certified Peer Support Specialists who offer a lived-experience perspective, bridging gaps in care, building trust, and providing support beyond the clinic including housing and employment navigation.
• Recovery Connect Mobile App Mobile application providing 24/7 access to recovery-focused interventions and virtual communication with counselors, allowing patients to track goals, access recovery tools, receive appointment reminders, and stay connected with their treatment team.
• Guest Dosing Program Courtesy methadone guest dosing program allowing current patients traveling or unable to visit their home clinic to receive medication at other CMS locations, with advance arrangement required, supporting treatment continuity across the multi-state network.
• Telehealth Methadone Treatment Telehealth services enabling patients to start methadone treatment remotely, subject to state laws and local opioid treatment program policies, designed to remove barriers to access for patients who cannot immediately reach a physical clinic.
• Urine Drug Screen Testing Comprehensive urine drug screening testing for fentanyl, opiates, oxycodone, barbiturates, benzodiazepines, cocaine, amphetamines, buprenorphine, methadone, and metabolites, performed at CMS's in-house lab in Scottsdale, AZ, to support clinical monitoring and patient retention.

Quantifiable outcome

• 90% of patients test negative for illicit opioids after one year of treatment
• +5 more outcomes

Named customers3 records

Segments5 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

Feature1 record

Partnerships

20 partnerships are on record, tiered core and minor.

• Urgent CarescoreStrategic or Co-development PartnerCMS partners with urgent care facilities to provide rapid intervention and referral pathways for individuals seeking opioid use disorder treatment. These partnerships enable same-day treatment access for patients presenting at urgent care settings.
• HospitalscoreStrategic or Co-development PartnerPartnerships with hospital systems for emergency department referrals and care coordination for patients with opioid use disorder, enabling continuity of care after hospital discharge.
• Police / Fire / EMScoreStrategic or Co-development PartnerFirst responder partnerships providing rapid intervention and resource linkage for individuals experiencing opioid overdose or substance-related emergencies. EMS and police can connect individuals to treatment resources.
• Detox / Residential Treatment CenterscoreStrategic or Co-development PartnerReferral relationships with detox and residential treatment facilities for patients requiring higher levels of care or transitioning between treatment settings.
• Recovery HousingcoreStrategic or Co-development PartnerPartnerships with recovery housing providers to support patients' housing stability during treatment, addressing social determinants of health that impact recovery outcomes.
• Behavioral Health / Mental Health FacilitiescoreStrategic or Co-development PartnerCoordination with mental health providers for patients with co-occurring disorders, ensuring integrated treatment approaches for substance use and mental health conditions.
• Primary Care PracticescoreChannel Partner/ Reseller/ DistributorReferral relationships with primary care providers who identify patients with opioid use disorder and connect them to CMS treatment services.
• Jails / PrisonscoreStrategic or Co-development PartnerCorrectional health partnerships providing medication-assisted treatment to incarcerated individuals, addressing the high rates of opioid use disorder in correctional populations.
• Specialty CourtscoreChannel Partner/ Reseller/ DistributorPartnerships with drug courts and specialty courts that mandate or recommend substance use treatment as an alternative to incarceration.
• Probation / ParolecoreChannel Partner/ Reseller/ DistributorReferral relationships with probation and parole departments for individuals under supervision who need substance use treatment services.
• Public Defenders / Defense AttorneysminorChannel Partner/ Reseller/ DistributorRelationships with public defenders and defense attorneys who can connect clients to treatment as an alternative to incarceration.
• Homeless ShelterscoreStrategic or Co-development PartnerPartnerships with homeless shelters providing low-barrier access to treatment for unhoused individuals struggling with opioid use disorder.
• Drop-in CenterscoreStrategic or Co-development PartnerPartnerships with drop-in centers offering harm reduction services and referrals to medication-assisted treatment for individuals not ready for traditional treatment settings.
• Overdose Prevention CoalitionscoreStrategic or Co-development PartnerCollaboration with community coalitions focused on preventing overdose deaths through education, naloxone distribution, and treatment access.
• Local GovernmentcoreStrategic or Co-development PartnerPartnerships with city and county governments to coordinate community health initiatives and address local opioid crises.
• State Government / SOTAcoreStrategic or Co-development PartnerCollaboration with state health agencies and State Opioid Treatment Authorities (SOTA) for regulatory compliance and treatment coordination.
• Public Health DepartmentscoreStrategic or Co-development PartnerPartnerships with public health agencies for disease prevention, overdose surveillance, and community health programs.
• County BoardsminorStrategic or Co-development PartnerRelationships with county health boards for local treatment coordination and resource allocation.
• VA / DCScoreStrategic or Co-development PartnerPartnerships with Veterans Affairs for veteran-focused treatment services and Child Services (DCS) for family preservation cases involving parental substance use.
• OBGYNscoreChannel Partner/ Reseller/ DistributorReferral relationships with OBGYN providers for pregnant and postpartum women with opioid use disorder, ensuring coordinated prenatal and addiction care.

Scale indicators8 records

Recent moves11 records

Expansion highlights6 records

Direct peers

• BayMark Health Services: Largest US OTP chain (formerly known as BAART and CRC Health), operating hundreds of methadone and buprenorphine clinics across 40+ states. Direct competitor with the same multi-modality MAT model, multi-state footprint, and reliance on Medicaid reimbursement as CMS.
• Pinnacle Treatment Centers: National provider of MAT and addiction treatment services operating under the New Season brand alongside residential and detox programs. Operates OTP clinics in many of the same states as CMS with comparable medication-assisted treatment offerings and Medicaid reimbursement reliance.
• CleanSlate Centers: Multi-state outpatient MAT provider (50+ locations) focused on buprenorphine and Suboxone for opioid and alcohol use disorders. Directly comparable same-day, walk-in low-barrier access model and target patient population to CMS.
• Behavioral Health Group (BHG): OTP chain operating dozens of methadone and buprenorphine clinics across multiple US states with similar counseling integration, Medicaid payor mix, and harm-reduction partnerships as CMS.
• Ideal Option: Multi-state outpatient MAT provider offering buprenorphine and Sublocade for OUD and alcohol use disorder. Comparable clinic-based low-barrier treatment model with similar geographic expansion strategy and patient demographic.
• Aegis Medical Systems: California- and multi-state OTP chain providing methadone and buprenorphine MAT with co-located counseling and primary care services. Operates on the same OTP regulatory framework and Medicaid reimbursement model as CMS.
• MedMark Treatment Centers: Multi-state OTP chain (operated under BayMark) offering methadone and buprenorphine MAT, counseling, and case management. Comparable medication menu, outpatient specialty clinic delivery model, and Medicaid patient mix to CMS.

Emerging players

• Bicycle Health: Tech-enabled virtual MAT provider offering buprenorphine treatment via telehealth across 30+ states. Represents a delivery-model competitor to CMS that bypasses clinic overhead and could capture a portion of CMS's suboxone patient volume, particularly outside methadone-eligible use cases.
• Workit Health: Virtual addiction treatment provider offering buprenorphine MAT, counseling, and recovery support via telehealth and asynchronous care. Comparable patient demographic and medication offerings but reaches them with significantly lower fixed-cost structure than CMS's clinic-based model.

Broad incumbents

• Hazelden Betty Ford Foundation: Large, nationally recognized non-profit addiction treatment provider offering residential, outpatient, MAT, and recovery services across multiple US sites. Compared to CMS, it operates at broader scale and across higher-acuity levels of care (including residential and inpatient), but serves overlapping OUD patient populations with similar evidence-based treatment philosophy and CARF accreditation.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks7 records

Key highlights7 records

Customer concentration

• Xx.com/CommMedicalServ
• YouTubeyoutube.com/channel/UChSqbUotPvibtx6REPyYG2g
• Facebookfacebook.com/CMSOpioidTreatment
• LinkedInlinkedin.com/company/community-medical-services
• Instagraminstagram.com/cmsgiveshope

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A3 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Community Medical Services